ArticleMolecular therapy. Oncology2025

Ruxolitinib and oHSV combination therapy increases CD4 T cell activity and germinal center B cell populations in murine sarcoma.

Ravi Dhital et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.